

## Keyword Index

15q11.2 ..... T167  
1H MRS ..... T128, W113, W177  
1NMPP1 ..... W160  
22q11 ..... 32, W32  
31P Magnetic Resonance Spectroscopy ..... W188  
5-HT2A receptor ..... W166  
5F-PB-22 ..... T250  
6-OHDA ..... W138  
7-Tesla ..... W101  
7q11.23 ..... W28  
[11C]DPA-713 ..... T140

### A

Abuse Potential ..... 4, T208, T249  
accelerometry, mood disorders, big data ..... W105  
acetylcholine ..... M4, M130, W64  
acoustic startle ..... M171, T78, W17  
Actigraphy ..... M114, W105  
Acute Stress ..... M104, T247, T253, W97  
Adaptive Behavior ..... T136  
addiction ..... 5, M222, M223, M224, M228, M233, M257, 14, 19, T51, T53, T171, T210, T212, T215, T216, T219, T242, T249, 28, 43, W126, W217, W242, W261, 51, 55  
adenosine ..... 31  
ADHD ..... T31, W26, W29, W34  
adherence ..... M153  
adjunctive treatment ..... T82  
Adjuvant thiamine ..... M81  
Adolescence ..... M24, M27, M28, M162, M257, T26, 31 T94, T171, T210, T244, T260, W31  
Adolescent ..... M26, M67  
Adolescent Alcohol ..... W237  
Adolescent binge drinking ..... 44  
Adolescent Depression ..... M30, T35, T102, W38  
Adolescent Development ..... T21  
Adolescent Stress ..... M33, T21  
Adolescents ..... T39, W37, W40  
adult neurogenesis ..... M99, T241  
advantages of the combination of therapies ..... T134  
affective disorders ..... M130  
African American ..... W109

aggression ..... T52, T149, W51  
Aging ..... M4, M146, M147, M151, T3, T4, T113, W2, W233  
aging and dementia ..... W3  
Agitation ..... M187  
AKT1/AKT3 ..... W151  
Alcohol ..... M28, M215, M222, M247, T211, T224, T261, W221, W235, W239  
alcohol and drugs ..... 60  
Alcohol consumption ..... T42, W258  
Alcohol dependence ..... M227, M241, M253, M259, T231, W209, W245, W255  
alcohol self-administration ..... M245, M256, W255  
Alcohol Sensitivity ..... T262  
alcohol use disorder ..... M219, T211, T220, T222, W253  
Alcohol withdrawal syndrome ..... W220  
Alcohol-preferring rats ..... W220, W236  
Alcohol-seeking ..... W236  
Alcohol-seeking behavior ..... T238, W142  
Alcoholism ..... M251, M256, M263, 11, 52  
alic ..... W136  
all is in the timing ..... T134  
allopregnanolone ..... T78  
alpha 5 ..... T212, W238  
alpha-7 nicotinic acetylcholine receptor ..... M25, T206, T207  
Altitude ..... T97, T236  
Alzheimer's Disease ..... M41, M43, 16, M145, T2, T43, T44, T141, W1, W4, W41, W42, W43  
Ambiguity ..... T217  
Amino acid mixture ..... T72  
Amish ..... 25  
AMPA ..... W95  
AMPA antagonist ..... M142  
AMPA glutamate receptors ..... W221  
AMPA receptor ..... M77, M186  
Amphetamine ..... M180, M260  
amplitude of low frequency fluctuation ..... M163  
Amygdala ..... M6, M14, M78, M97, M131, M211, T14, T16, T28, T35, T90, T172, W25, W144, W237  
amygdala-based networks ..... T26  
Amyloid ..... T2  
Amyloid Precursor Protein ..... W41  
anatomical connectivity ..... W134  
anesthesia ..... M121

**Keyword Index**

- Anesthetic ..... T54, W137  
 Anger ..... M107  
 anhedonia ..... T254, W37, W106, W108, W232  
 Animal Model ..... 9, M57, T8, T85, T160, T181, T190  
 Animal Models ..... M76, M157, M263, 18, T65, T70, T91, W79, W146  
 ankyrin-3 ..... M99  
 anorexia nervosa ..... M49, T47, W47, W48  
 anterior cingulate cortex ..... T2, T101, T130, W51, W60, W84, W122, W163  
 anterior prefrontal cortex ..... T192  
 anti-ADHD like action ..... W35  
 Antidepressant ..... 4, M35, M62, M77, M83, M167, T35, T91, T102, T109, T112, W66, W78, W87, W113, W114  
 antidepressant response ..... M85, T85  
 Antidepressants ..... M59, T56, T58, T61, T81, T101, W70, W97, W111  
 Antipsychotic ..... M157, M159, M167, T201, W39, W168, W174  
 Antipsychotic agents ..... T150  
 Antipsychotic induced weight gain ..... M177, W39  
 antipsychotic medication ..... W206  
 Antipsychotic monotherapy ..... M206  
 Antipsychotic switching ..... M193  
 Antipsychotic Treatment ..... M168, M170, M190, M191, W184  
 antipsychotic-naïve ..... W152  
 Antipsychotic-naïve first-episode schizophrenia ..... M190, 12  
 Antipsychotics ..... T157, T174, T181, W132, W156  
 antisocial personality disorder ..... M148, M150  
 Anxiety ..... M15, M31, M88, T13, T14, T17, T59, T63, T67, T120, T148, W6, W8, W10, W15, W20, W81, W87, W94, W126, W144, W237, 52, 55  
 Anxiety disorders ..... M9, M12, M20, T16, 30, 41, W16, W22, 6  
 anxiety state ..... T9  
 anxiolytic ..... W87  
 Anxious distress ..... M88  
 apathy ..... W73  
 Appetite ..... T121  
 Appetitive Hormones ..... 5, T137  
 Arc ..... W250  
 Arcuate ..... M126  
 aripiprazole once-monthly 400 mg (AOM 400) ..... T187, W154  
 ASD ..... M8  
 aspirin ..... T76  
 associative learning ..... M213, W251  
 associative-striatum ..... W177  
 ASSR ..... M160, W186  
 astrocytes ..... M133  
 astroglia ..... 54  
 at-risk ..... M199, T15, W17  
 Attention ..... M136, M162, M226, T7, T111, T129, T130, T255, W117  
 Attention Deficit Hyperactivity Disorder ..... T53  
 attentional bias ..... M98, T59  
 attentional bias modification ..... W229  
 atypical antipsychotic drug ..... M56, T62, W172  
 Atypical antipsychotics ..... M34, M55, M65, M186, T79, T114, T185, W56  
 Auditory cortex ..... M197  
 Auditory hallucinations ..... T166, W202  
 augmentation ..... M65  
 Autism ..... T25, M38, T34, T132, T142, W27  
 Autism & depression ..... 57  
 Autism spectrum disorder ..... M128, M241, W43, W91, W166  
 autism Spectrum Disorders ..... M37, M44, M36, T33, T37, T144, W30, W204

**B**

- Balb/c mouse ..... M36  
 Basal Ganglia ..... M232, T105  
 basolateral amygdala ..... M119, M255  
 bath salts ..... M250  
 BB-22 ..... T250  
 BDNF ..... M62, M67, M111, M202, T74, T95, T188  
 Behavior ..... M242, 37, 55  
 behavioral despair ..... T68  
 behavioral economics ..... T242  
 behavioral inhibition ..... T53, W25, W142  
 Behavioral Pharmacology ..... M231, T218, T237, W41, W50  
 behavioral variability ..... W26  
 Behaviors ..... M140  
 benign neutropenia ..... M172  
 benzodiazepine ..... M167, W114  
 beta arrestin ..... M165, M169, M261, 53  
 beta-amyloid peptide 1-42 ..... T42  
 big data ..... T96  
 binge drinking ..... M263, T211, T218  
 binge-eating ..... T46, W49  
 Binge-eating disorder ..... W46, M47, M48, M223  
 Bioenergetics ..... M199  
 Bioinformatics ..... T144  
 Biomarker ..... M41, M58, M111, T27, T76, T95, T141, W66, W100, W159  
 Biomarker risk assignment algorithm ..... M108  
 biomarkers ..... T8  
 bipolar ..... M199  
 bipolar depression ..... T77

- Bipolar Disorder ..... M55, M67, M82, M91, M93, M101, M110, M112, M114, M115, M147, M153, M188, T64, T163, T71, T76, T96, T104, T108, T111, T119, T194, W63, W71, W77, W79, W82, W88, W89, W99, W202
- Bipolar I Depression ..... T62, W56
- BNST ..... M14, T120
- Body Dysmorphic Disorder ..... M21
- BOLD imaging ..... M236, T12
- Borderline Personality Disorder ..... M149, T146, W147, W148, 47
- Brain ..... T56, T136
- brain activation ..... 38
- Brain Anatomy ..... T130
- Brain Based Markers for Depression ..... M90, M98
- brain connectivity ..... M1, T32
- Brain development ..... M35, M50, T41, W25, W181
- brain hemispheres ..... T134
- brain imaging ..... 30, 52
- Brain Stimulation ..... T77, 43, W102, W103, W112, W121
- brain structure ..... W124, W141, W181, W219
- brain volume ..... T74
- brain volumes ..... T200, W21
- Brain waste removal ..... 16
- Brain-Derived Neurotrophic Factor ..... M174
- breast cancer ..... M139
- Brexipiprazole ..... M88, M107, M187, M193, T88
- bulimia nervosa ..... M50
- Buprenorphine ..... T228, T232, W72
- buprenorphine maintenance ..... M258
- bupropion ..... T80

## C

- c-Fos ..... M99, M212
- CACNA1C ..... T3, T119
- caffeine ..... M250, T248, 31, W208
- calcium ..... T119
- calcium imaging ..... M213, T16, W131, W211, 55
- Cannabidiol ..... W225, W259
- cannabinoids ..... M217, M221, T250, 28
- cannabis ..... M15, 19, T210, T234
- Cannabis Dependence ..... M154, M247, M262, T168, T256, W227, W241, W260
- cannabis use ..... T171, T173, T175, T260, W216
- CANTAB ..... M41
- Cardiac Reactivity ..... T262
- Cardiometabolic Risk ..... W39, W132, W190
- Career Development ..... M124
- cariprazine ..... M156, M204, M206, T170
- catenin cadherin-associated protein, alpha 2 ..... M53
- CB1 receptor ..... T250, W227
- CBT ..... M18, T22
- CCK-4 ..... M16
- Central autonomic network ..... M80, W121
- Central nucleus of the amygdala ..... W59, W221
- Cerebral Blood Flow ..... M49, W235
- Child abuse and neglect ..... T39, W233
- child offspring ..... T104
- childhood maltreatment ..... M39
- Childhood Onset Bipolar Disorder ..... 23
- Childhood trauma ..... M26, M210, W145
- childhood urban-rural upbring ..... W207
- Children and Adolescents ..... T27, T98, W39
- choice ..... M216, T252
- choline ..... M25, T157, T206
- cholinergic system ..... W43, W64
- chromatin ..... W27, W139
- chronic ..... T190
- chronic mild stress ..... T73, W72
- chronic pain ..... W86, W143, W230
- chronic social defeat ..... M96
- chronic stress ..... M104, T60, T138, W50, W75, W110, W240
- cingulate ..... T86
- circadian ..... W239
- circadian rhythm ..... M12, M111, M139, M147, T258
- citalopram ..... T80
- cladistics ..... W158
- CLARITY ..... W194
- Clathrin nanoparticles ..... W128
- claustrum ..... T130, T182
- clinical high risk ..... T155, T161, T172
- Clinical trial ..... M83, W129, W169, M86, M128, M241, T195, W43, W91, W166
- Clinical Trial Design ..... W57
- Clinical Trial Methodology ..... 15, 24
- CLOCK ..... T258
- clomipramine ..... W122
- clonidine ..... M258
- Clozapine ..... M172, T185, M191, T203, W175, W203
- Cluster Analysis ..... T204
- CNS antibody delivery ..... W128
- CNS Clinical Trials ..... M253, T222
- CNV ..... T25, W32
- co-abuse ..... M263, T261

**Keyword Index**

- Cocaine . . . . . M213, M214, M220, M222, M231, M233, M243, M250, T183, T216, T219, T229, T233, T235, T253, T261, W210, W217, W228, W242, W243, W250
- cocaine addiction . . . . . M223, M225, M236, M237, M239, M240, M248, M252, T251, T252, T254, T258, T259, 28, W35, W212, W214, W219, W222, W246, W247, W254
- cocaine seeking . . . . . M211, M255, W222, W231, W240, 54
- cocaine-related disorders . . . . . M220
- Cognition . . . . . M4, M41, M45, M72, M112, M120, M154, M179, M181, M192, T3, T82, T98, T105, T111, T159, T162, T186, T191, T204, T234, T244, W4, W89, W119, W155, W162, W165, W171
- cognitive aging . . . . . M1, M3, T2
- cognitive behavior therapy . . . . . M26, M100
- cognitive behavioral therapy . . . . . M23, M95
- cognitive control . . . . . M90, T117, T173, W23, W51, W226
- cognitive control network . . . . . M95
- Cognitive Decline . . . . . T87, T113
- cognitive deficit . . . . . T196
- Cognitive Enhancement . . . . . M28, M130, T24, W125
- Cognitive Functioning . . . . . T93
- Cognitive impairments . . . . . W188
- Cognitive Neuroscience . . . . . M26, 17, T209, 51
- cognitive reappraisal . . . . . M149
- cognitive remediation . . . . . M166, T152, T164, W205
- Cognitive Resilience . . . . . T54, W1
- cognitive training . . . . . 17
- cognitive/emotional task performance . . . . . W116
- combat . . . . . T15
- combat veteran . . . . . M17, W21
- community based family study . . . . . T108
- community structure . . . . . T122
- compensatory cognitive training . . . . . T151
- compulsion . . . . . W9
- Compulsive eating . . . . . T49
- compulsivity . . . . . M51, M52, M248, 14
- computational modeling . . . . . T51, W127
- COMT gene . . . . . W145
- concerns . . . . . 60
- conditioned cue . . . . . W7, W142
- conditioned place preference . . . . . T229, T236, W211, W249
- Conditioned responses . . . . . W120
- conflict of interest . . . . . 35
- Connectivity . . . . . M224, T18, T117, W76, W165, W191
- Connectivity strength . . . . . T90
- connectome . . . . . T75, W55, W134
- connectomics . . . . . T122, W192
- consciousness . . . . . T134
- Context . . . . . T225, W7
- coping . . . . . M23
- copy number variation . . . . . M37, 25
- cortex . . . . . M137, W130
- cortical dynamics . . . . . W192
- Cortical Inhibition . . . . . T27, T168, W112
- Cortical neurons . . . . . T238
- cortical thickness . . . . . W36
- cortico-striatal plasticity . . . . . M234
- corticoaccumbens circuit . . . . . W49
- corticosterone . . . . . M61, T23, W94
- Corticotropin-releasing factor (CRF) . . . . . W214
- Corticotropin-Releasing Hormone . . . . . M76
- Cortisol . . . . . M10, M14, M109, M139, T84, T86
- COX-1 . . . . . M54
- CpG Methylation . . . . . M9
- CR845 . . . . . M129
- craving . . . . . T137, T230, T256
- CREB . . . . . T42, T115
- CRF . . . . . T233, W5
- CRH . . . . . T67, W22, W115
- CRHBP . . . . . W14
- CRP . . . . . M120, T100
- CSF . . . . . M94
- CSF Biomarkers . . . . . T87
- Cue Reactivity . . . . . W218
- cue reinstatement . . . . . M221, M225, W225
- Cue-Exposure . . . . . T226, T230
- cue-reactivity . . . . . W248
- cues . . . . . W212
- Cyberball . . . . . T228
- cyclic AMP . . . . . W66
- CYP2C19 . . . . . M59
- cytokines . . . . . M13, M94, M117, 21, T100, T105, W61, W107, W135, W204
- Cytoprotection . . . . . M143
- cytoskeleton . . . . . T57
- D**
- D-amino acid oxidase . . . . . W199
- D-serine . . . . . M214
- D2 receptor . . . . . M169, W107, W151, W166, 53
- Data sharing . . . . . 15
- Data transparency . . . . . 15
- DBS . . . . . T46, W9, 56, 59

**Keyword Index**

- de novo ..... M37  
 de novo mutation ..... M174, M201, W33  
 Decision Making ..... M131, M202, M215, T13, T51, T217  
 declarative memory ..... M7  
 deep brain stimulation ..... M38, M90, W100, W209  
 default mode network ..... M60, M141, T101, W11, W101  
 default network ..... T180  
 delay discounting ..... 13  
 delta9-tetrahydrocannabinol ..... W225  
 Delusions ..... T192  
 Dementia ..... T145  
 dendrites ..... M196, W181  
 Dendritic Spine ..... 1, M161, M233, T102  
 dentate gyrus ..... T19  
 depot ..... M153  
 Depression ..... 4, M15, M57, M60, M61, M69, M72, M75, M84, M87, M91, M96, M98, M102, M113, M118, M121, M140, T10, T56, T63, T68, T70, T73, T77, T86, T91, T92, T97, T99, T101, T184 38, 40, W58, W63, W64, W65, W70, W74, W76, W80, W87, W90, W91, W97, W98, W107, W110, W123, 52, 56, 59  
 depressive disorders ..... M85  
 Design ..... 8  
 development ..... T4, T131, T202, T234, 38  
 Developmental ..... T181, W20  
 Developmental Psychopathology ..... M45, 20  
 developmental trajectories ..... M34, 24  
 Dextromethorphan/Quinidine ..... M145, T145  
 diabetes ..... T139  
 diagnostic criteria ..... 51  
 diagnostic specificity ..... W158  
 Dietary supplement ..... T116  
 diffusion ..... M106  
 Diffusion tensor imaging ..... T32, W194  
 Diffusion Weighted Imaging ..... M60, T205, T219  
 Digital Health Feedback System ..... M200  
 dimensions of psychosis ..... W192  
 diphtheria toxin ..... W187  
 Direct pathway ..... M137  
 DISC1 ..... M228, W149, W193  
 Disease prevalence ..... M143  
 disease progression ..... M139  
 disparities ..... M2  
 disruptive mood dysregulation disorder ..... T29  
 divergent transcription ..... T188  
 DKI ..... M106  
 DLPFC ..... M196, T144, W165  
 DNA Methylation ..... M197, W213  
 DNA sequencing ..... T163  
 domesticate ..... W146  
 Dopamine ..... M28, M79, M165, M168, M176, M177, M178, M179, T192, M198, M212, M215, M217, M218, M226, M238, M248, M262, T31, T73, T135, T180, T207, T212, T227, T254, T258, W45, W69, W98, W106, W115, W171, W174, W181, W212, W217, W218, W257, W261, W262, 53  
 Dopamine (D2, D3) receptors ..... M159, M175, M176, M177, M216, T239, W244, W247  
 dopamine 2 receptor ..... W170  
 Dopamine 3 receptor imaging ..... W128  
 dopamine d4 ..... W203  
 dopamine transporter ..... M232, T31, W73, W123, 57  
 Dopaminergic system ..... T67, W58  
 Dopmaine ..... T136  
 Dopmaine Receptors ..... M48  
 dorsal caudate ..... T150, W177  
 Dorsal striatum ..... M137, M248, W69  
 dorsolateral prefrontal cortex ..... M42, M152, W84, W122  
 dorsolateral striatum ..... M211  
 Dose-response Analyses ..... M55  
 Down Syndrome ..... W140  
 downregulation ..... W227  
 DRD2 locus ..... T174, W151  
 DREADD ..... M42, T218, T233, W15, W49  
 DREADD Receptor ..... T214  
 DREADDs ..... M23, T235  
 drinking ..... W215  
 drug abuse ..... T252  
 Drug Discovery - new approaches ..... 50  
 drug discrimination ..... M250  
 DTI ..... M40, T176, W119  
 duloxetine ..... W86  
 Dup7 ..... W28  
 Dynorphin ..... T218

**E**

- Early intervention ..... 6, W149  
 Early life stress ..... M32, M39, M87, T39, T110, T139, W69  
 Early Phase Drug Development ..... W253  
 early psychosis ..... W206  
 early sensory signal processing ..... T24  
 early signs ..... 45

**Keyword Index**

Eating disorder ..... 5  
 Eating Disorders ..... M47, T48, W46, 36  
 ecological momentary assessment ..... M258  
 ECT ..... W76, W103  
 Editorial ..... 8  
 education ..... T133  
 EEAT2 ..... T64  
 EEG ..... M121, M164, M184, T155, W103, W193, W208  
 EEG biomarkers ..... T146, T230, W68  
 Effort ..... W157  
 Electroconvulsive therapy ..... M38, M68, T77, T107, T203, W55, W68, W90, W112  
 electroencephalography ..... M160  
 Electronic cigarette (e-cigarette) ..... M242  
 electrophysiology ..... M131, M169, M186, T43, T88, T130, T142, T255, 37, W83  
 emergence ..... M121  
 emotion ..... T86  
 Emotion Modulation ..... T7  
 Emotion Perception ..... W12  
 Emotion processing ..... M66, M78, T12, T71, T228, W116  
 emotion regulation ..... M32, T12, T164  
 emotional response inhibition ..... M152, T71  
 Emotional stress ..... M57  
 Emotional Test Battery ..... M72  
 endocannabinoid ..... M15, T110  
 Endocannabinoids ..... W94, W147  
 Endomicroscopy ..... W211  
 endophenotype ..... T25, M112, M171, 13, T36, T84, 39  
 endophenotypes ..... T45, T96, T108  
 endurance training ..... M166  
 energy homeostasis ..... M49  
 epidemiology ..... M45, T5, T231  
 Epigenetic ..... 3, 11, T144, W52, W243, 49  
 Epigenetics ..... M9, M35, M39, M214, T60, T64, T165, T201, W41, W96, W140, W213, W254  
 epilepsy ..... M142, M144  
 episodic memory ..... 41, W197, W207  
 ErbB4 ..... W160  
 ERP ..... 2, M184, T156, T230, W198  
 ERPs ..... M160, W117  
 Escitalopram ..... M21, T80  
 Esketamine ..... M62, T91, T93, T106, W57  
 eSource ..... W150  
 Estradiol ..... M3, M4, M113, T118  
 estrogen ..... T66  
 estrogen receptor ..... T11  
 ethanol ..... M251, W31  
 ethics ..... 35

evoked response potential ..... M173  
 Excitability ..... M243, W102  
 executive function ..... M67, M90, M135, M224, T2  
 exercise ..... W133, W246  
 exome ..... W148  
 exome sequencing ..... M37  
 Exposure therapy ..... M10, M18  
 extended reward network ..... W134  
 Extinction learning ..... M245, 6  
 Extinction memory recall ..... W118  
 extracellular matrix ..... T251  
 extrastriatal dopamine D2/3 receptors ..... W152

**F**

FAAH ..... T256, W14  
 FAAH inhibitor ..... T256  
 face perception ..... M173  
 face specific processing ..... M173  
 factor analysis ..... W99  
 familial risk ..... T5  
 familiarity ..... T193  
 Fast-acting Antidepressant ..... M111, T65, T70, W58, W96  
 fatty acids ..... 27, M118  
 fear ..... T14, W146  
 Fear conditioning ..... M6, M13, M20, M138, T6, T22, T172, W5, W13, W17, W20  
 Fear extinction ..... M138, T6, T19, T22, W7, W9, W13, W17  
 fear generalization ..... 10, 41  
 fear processing ..... 41  
 FEAST ..... W103  
 Feedback negativity ..... T156  
 Female ..... M57  
 Field trial ..... M101  
 first episode schizophrenia ..... M163, T173, W184, W205  
 First-episode psychosis ..... T205, W168, W177, W197  
 first-episode schizophrenia ..... T149, T155  
 FKBP5 ..... M39, W74  
 flibanserin ..... T208  
 Fluorescence-activated cell sorting ..... T182  
 fMRI ..... 2, M1, M3, M91, M98, M122, M132, M173, M224, M226, M246, M249, 17, T7, T17, T59, T117, T121, T125, T127, T128, T137, T172, T173, T257, W26, W37, W38, W47, W65, W102, W116, W118, W120, W137, W144, W157, W165, W235, W248  
 fMRI faces paradigm ..... T52  
 fMRI Functional Connectivity ..... M19, M80, M95, T180, W133, W222

**Keyword Index**

fMRI resting state ..... M163, W10, W76  
 fMRI, anxiety, threat ..... W23  
 fMRI/imaging genetics ..... 19, T159, W1, W34, W218  
 FMRP ..... T167  
 fNIR ..... 2, W232  
 Food Addiction ..... W46, W244  
 forced swim test ..... T97, W97  
 Fractional-anisotropy ..... M106, T219, T240  
 fronto-striatal networks ..... W151  
 Functional Capacity ..... M170, T139  
 Functional connectivity ..... T69, T216, W179  
 functional impairment ..... W88  
 functional magnetic resonance imaging ..... T66, W180, W207  
 functional neuroimaging ..... M7, M203, 21, T166, W106, W216  
 functional outcome ..... W189  
 Functional Selectivity ..... M165, M176, M261, W170  
 Funding ..... M124  
 FXR1P ..... M66

**G**

g protein signaling ..... M261, 27  
 G-protein ..... W66  
 GABA ..... M74, M84, M178, T247  
 GABAA ..... T78, W149, W173  
 GABAB ..... M259  
 GABAergic cells ..... W187  
 GABAergic circuitry ..... W155  
 GABAergic interneurons ..... M31, T153, W183, W262  
 Gabapentin ..... W53  
 GAD65/67 mRNA ..... M48  
 gait ..... T25  
 Galanin ..... W258  
 gamma oscillation ..... T155, W185, W186  
 gender ..... M148, T90, T243, W38  
 Gene environment interaction ..... M228  
 gene expression ..... 11, T8, T10, T178, T182, T229, 42, W48, W70, W84, W143, W239, 49  
 generalized anxiety disorder ..... W12  
 genes ..... 48  
 genetic ..... M43, M183, 13, W79, W115  
 genetic mouse model ..... 7, T25, T57, T229, 32, W239  
 genetics ..... M120, M130, M171, M174, M219, M259, 25, T127, T132, T157, 39, W78, W111, 48  
 Gene-environment interaction ..... T48, W207  
 genome editing ..... M229  
 Genomics ..... M123, 34

geography and drug addiction ..... T236  
 Geometry ..... T148  
 Global Deterioration Scale ..... T1  
 Global outreach ..... 26  
 GLT-1 ..... M243, T253, W220  
 glucocorticoid ..... M94, T246  
 glucocorticoid receptor ..... M255, W74, W97  
 Glutamate ..... M16, M30, M51, M86, M125, M175, M178, M222, M262, T64, T104, T127, T161, T178, T206, T207, T213, W96, W177, W220, W249, 29  
 glutamate GABA ..... M198, T43, T177, W44  
 glutamate receptor activity ..... M197  
 glutamate transport ..... T198  
 glutamate/glutamine cycle ..... M30  
 glutamatergic synapses ..... W204  
 glutamatergic transmission ..... W8  
 Glutamine ..... M30  
 glutathione ..... M22  
 glycogen synthase kinase-3 ..... W95  
 glycosylation ..... M207  
 Glymphatic pathway ..... 16  
 Gonadal Hormones ..... M105, T118, 36  
 GPCR ..... M79, 50  
 GPHN ..... W14  
 Graph theory ..... T99, W68  
 GSK3 ..... M66  
 guanfacine ..... M97  
 guanylyl cyclase ..... M205  
 Gut Microbiome ..... T40, T63, W126, W141  
 GWAS ..... M93, M181, 13, 22, W21, W78  
 gyration ..... W28

**H**

habit ..... M248, 22, T213  
 hallucinogen ..... W124, W178, 52  
 haloperidol ..... T178  
 harm avoidance ..... M8, T47  
 Harm reduction ..... W259  
 hbA1c ..... T139  
 HDAC ..... T179  
 HDAC inhibitors ..... W41  
 head-to-head clinical trial ..... T187, W154  
 health-related quality of life ..... T187, W154  
 healthy individuals ..... W122  
 Heart Rate Variability ..... M80, T15, T262  
 Heroin ..... M254  
 heterogeneity ..... W99

**Keyword Index**

- heterogeneity ..... W77  
 high fat diet ..... 33  
 high risk ..... 12  
 high risk psychosis ..... M27, W182, W189  
 Hippocampal Function ..... W1  
 Hippocampus ..... M11, M64, M182, T19, T57, T109, T110, T148, T178, T225, T235, T241, W107, W145, W211  
 hIPSCs ..... 32  
 Histamine ..... W30  
 Histone ..... T144, W96, W140  
 Histone methylation ..... W237  
 HIV ..... M75, T138  
 HIV-1 ..... W73  
 HMGB1 ..... M64  
 Hoarding Disorder ..... W24  
 homer ..... W249  
 Hostility ..... M187  
 Hot Flashes ..... M113  
 HPA axis ..... M10, M39, M210, T224, W31  
 Hsp90 ..... W74  
 HTR3B ..... W14  
 hub analysis ..... T122  
 Human Factors Testing ..... M200  
 human laboratory ..... M216, M239, T222  
 Human Neuroimaging ..... M50, M134, M216, M236, M254, 17, 19, T18, T89, T138, T143, T244, W18, W21, W23, W124, 44, 47, 51  
 humans ..... T8, T72  
 hunger ..... M49  
 Huntington's Disease ..... W139  
 hypersexual disorder ..... M210  
 Hypothalamic development ..... M126  
 Hypothalamic-Pituitary-Adrenal axis ..... T21, T23, T84  
 hypothalamus ..... M105, T16  
 Hypoxia ..... T236
- I**
- ibudilast ..... W253  
 imaging ..... M249, M257, T142, T227  
 imaging genetics ..... T26, W42  
 Immune ..... M183, M188  
 immune mechanisms ..... 33, W153  
 impulsiveness ..... T89  
 impulsivity ..... M46, M51, M52, M53, M99, 13, T31, T53, T239, W49, W209, W245, 44  
 in vitro cellular model ..... T167  
 In vivo Imaging ..... 1  
 inbred mouse strains ..... T124
- Incentive motivation ..... M218, W258  
 incentive salience ..... W251  
 inclusion and exclusion ..... W216  
 incubation ..... W240  
 individual differences ..... M135, M252, T6, T125, W25, W126, W210, W251  
 Induced pluripotent stem cells (iPSCs) ..... T119, T167, W48, W130, 48  
 infant ..... M25, W25  
 infertility ..... W16  
 inflammation ..... M13, M64, M118, M120, M133, 21, T105, T160, 27, W89, W106  
 Inflammatory Markers ..... M54, W61  
 informatics ..... T75  
 infralimbic cortex ..... T73, T213, W245  
 Inhibition ..... T61, W145  
 Inhibitory control ..... M260, T216, W50  
 inhibitory synaptic transmission ..... W183  
 innovative methods ..... W169  
 Insula ..... T215, T243, W47, W179, W241  
 Insula Connectivity ..... W85  
 Insulin ..... M177, W8  
 insulin resistance ..... M85, T83  
 Insulin-like growth factor 1 ..... T37  
 intellectual disability ..... W27  
 Intelligence Quotient ..... W119  
 interleaved TMS/fMRI ..... W102  
 Interleukin-6 ..... M13  
 internal capsule ..... W136  
 international ..... W129  
 internet ..... M52, M100, W24  
 interneuron ..... T177  
 Interoception ..... T14, T121, W47  
 interpeduncular ..... W252  
 interpretation bias ..... T29  
 intracranial self-stimulation ..... T183, T208, W108  
 Intranasal ..... T93  
 Intranasal formulation ..... T106  
 intravenous administration ..... W224  
 ion channel ..... M157  
 iPSC ..... T126  
 Irritability ..... M107, T29, T59  
 ITI-007 ..... W174  
 IV Alcohol ..... T262
- K**
- Kalirin ..... 1, M161  
 kappa agonist ..... M129

- kappa opioid receptor . . . . . M104, M256, T247, W50, W62, W75, W255  
 KCa2 channels. . . . . M245, W257  
 Ketamine. . . . . M18, M61, M62, M73, M77, M160, M208, 22, T74, T91, T94, W78, W95, W108, W113, W114  
 kinases . . . . . T65  
 Kynurenic acid . . . . . T128, T131, 29  
 kynurenone . . . . . T4, W195

**L**

- Lactate . . . . . W113  
 Large Scale Networks. . . . . T34, W34, 56  
 Laser Capture . . . . . W200  
 Late-life Depression. . . . . T87, T113, T117  
 Lateral Habenula . . . . . M79, T55, T73, W94, 59  
 Lateral Septum . . . . . T235  
 Learning . . . . . T136  
 learning and memory. . . . . T49, T128, W107, W254  
 Leptin. . . . . T20  
 lesion . . . . . W144  
 leukocyte telomere length. . . . . M85  
 levetiracetam. . . . . W3  
 life stress. . . . . M75  
 Linkage. . . . . M118  
 lipid rafts . . . . . W66  
 lipids . . . . . M118  
 liquid chromatography/mass spectrometry . . . . . M74  
 Lisdexamfetamine . . . . . M46, M47  
 Lithium. . . . . M143, W71  
 Lithium response. . . . . M82  
 Locus coeruleus. . . . . M33, W117  
 Locus coeruleus. . . . . M209  
 long noncoding RNA. . . . . M20, T52, W213  
 Long Term Potentiation. . . . . T247  
 long-acting-antipsychotic. . . . . T195  
 longitudinal. . . . . M50, T234  
 LPS. . . . . W81  
 LSD1. . . . . W237  
 lurasidone. . . . . M55, T92, W172, W203  
 Luzindole . . . . . T109

**M**

- Machine learning. . . . . M108, T96, W36  
 MADRS. . . . . W150  
 Magnetic Resonance Imaging. . . . . W18  
 magnetic resonance spectroscopy. . . M16, M208, T157, W44

- Magnetic seizure therapy . . . . . M68, W68  
 magnetization transfer . . . . . M141  
 maintenance treatment. . . . . M235, T112  
 Major depression. . . . . M56, M63, M78, M80, M86, M92, 10, T58, T60, T83, T95, T98, T105, T107, T118, T121, W55, W72, W93, 46, 58  
 major depression history . . . . . T103  
 major depression, post-traumatic stress disorder . . M95, W59  
 Major Depressive Disorder. . . . . M55, M58, M68, M81, M89, M100, M111, M188, T74, W91  
 Major Depressive Disorder (MDD). . . . . M71, M117, T62, T69, T82, T100, T114, W61, W86  
 Major Psychiatric Disorders. . . . . M202  
 mania . . . . . W63, W71, W79, W192  
 marijuana . . . . . T210, T244, T248  
 Maronutrient. . . . . W258  
 mass spectrometry. . . . . T198  
 Maternal. . . . . M140  
 maternal separation. . . . . T28  
 Matrix Metalloproteinase-9 (MMP-9) . . . . . 18  
 MCH. . . . . M140  
 MDD. . . . . M70, M88, M107, W113  
 MDPV. . . . . M250  
 mecamylamine. . . . . M136  
 Medial frontal cortex. . . . . M31  
 Medial Prefrontal Cortex. . . . . M11, M23, M33, M78, M182, M185, M2015, T99, T102, T182, T206, T255, T259, 36  
 Medication adherence . . . . . W206  
 Medication Development. . . . . T222  
 Medicinal Marijuana. . . . . T249  
 mediodorsal thalamus . . . . . W191  
 Medium Spiny Neuron. . . . . M213, W228  
 Melatonin. . . . . T109  
 memantine . . . . . T151  
 Memory . . . . . 18, T3, T42, T111, T191  
 Memory and Learning. . . . . M24, M214, T150, T260, W82  
 Memory Consolidation and Extinction. . . . . T19  
 Memory Encoding and Retrieval. . . . . M3, M119, W82  
 menopause . . . . . M3, M4, M87  
 mental health service use. . . . . M2  
 Mentoring. . . . . M124, 26  
 meta-analysis. . . . . W61, W93, W175  
 metabolic safety. . . . . M156  
 metabolic syndrome. . . . . T185, T201  
 metabolism. . . . . T20  
 Metabolomics. . . . . M128

**Keyword Index**

- metabotropic glutamate receptor . . . M<sub>70</sub>, M<sub>123</sub>, T<sub>82</sub>, T<sub>159</sub>, T<sub>221</sub>, W<sub>173</sub>
- metals . . . . . W<sub>159</sub>
- Methamphetamine . . . . . M<sub>234</sub>, M<sub>263</sub>, T<sub>236</sub>, T<sub>239</sub>, T<sub>240</sub>, T<sub>241</sub>, W<sub>224</sub>, W<sub>249</sub>
- Methionine . . . . . T<sub>181</sub>
- methods . . . . . 60
- Methylphenidate . . . . . T<sub>13</sub>, T<sub>24</sub>
- mGlu2/3 receptor . . . . . M<sub>77</sub>
- mGlu5-PAM . . . . . W<sub>4</sub>
- mgur5 . . . . . W<sub>156</sub>
- mGluR5 receptors . . . . . M<sub>245</sub>
- Mice . . . . . M<sub>138</sub>, M<sub>202</sub>
- microarray . . . . . T<sub>197</sub>
- Microdialysis . . . . . M<sub>12</sub>, T<sub>207</sub>, W<sub>257</sub>, W<sub>261</sub>
- microglia . . . . . M<sub>64</sub>, 33
- microglial activation . . . . . W<sub>182</sub>
- MicroRNA . . . . . M<sub>102</sub>, T<sub>10</sub>, T<sub>124</sub>, T<sub>199</sub>
- mild cognitive impairment due to AD . . . . . M<sub>41</sub>
- Mild Traumatic Brain Injury . . . . . T<sub>140</sub>
- minocycline . . . . . T<sub>76</sub>
- Minor Tobacco Alkaloids . . . . . T<sub>237</sub>
- Mismatch Negativity . . . . . T<sub>152</sub>, T<sub>202</sub>, W<sub>198</sub>
- missense mutations . . . . . T<sub>163</sub>
- Mitochondria . . . . . T<sub>197</sub>, W<sub>185</sub>, W<sub>228</sub>
- mitochondrial function . . . . . W<sub>3</sub>
- Mixed features . . . . . T<sub>92</sub>
- mobile health . . . . . W<sub>206</sub>
- Mobile phones . . . . . M<sub>101</sub>
- Mobile technology . . . . . W<sub>105</sub>
- moderators . . . . . M<sub>253</sub>
- molecular mechanisms . . . . . M<sub>196</sub>, M<sub>209</sub>, T<sub>10</sub>, 50, 54
- monkey . . . . . M<sub>42</sub>, T<sub>252</sub>, W<sub>161</sub>
- monkeys . . . . . W<sub>244</sub>
- Monoamine oxidase A . . . . . M<sub>150</sub>, T<sub>116</sub>
- monoamines . . . . . T<sub>88</sub>, W<sub>83</sub>
- Mood . . . . . M<sub>66</sub>, T<sub>137</sub>
- mood and addiction . . . . . M<sub>246</sub>
- mood and anxiety disorders . . . . . M<sub>103</sub>, T<sub>84</sub>, W<sub>105</sub>
- mood disorder . . . . . M<sub>56</sub>, M<sub>116</sub>
- mood disorders . . . . . M<sub>109</sub>, T<sub>77</sub>, T<sub>89</sub>, T<sub>108</sub>, 30, W<sub>85</sub>
- morphine . . . . . M<sub>230</sub>, T<sub>225</sub>
- morphological and resting state brain activity . . . . . M<sub>237</sub>
- motivated drug taking . . . . . M<sub>231</sub>
- motivation . . . . . M<sub>125</sub>, M<sub>155</sub>, M<sub>238</sub>, T<sub>156</sub>, T<sub>212</sub>, W<sub>157</sub>, 21
- motor stereotypies . . . . . W<sub>33</sub>
- mouse behavior . . . . . M<sub>162</sub>, M<sub>230</sub>, W<sub>70</sub>, W<sub>196</sub>
- mouse brain . . . . . W<sub>194</sub>
- mouse model . . . . . T<sub>158</sub>, T<sub>185</sub>, T<sub>218</sub>, 45
- Mouse models . . . . . W<sub>170</sub>, W<sub>183</sub>
- MPTP . . . . . W<sub>138</sub>
- MR spectroscopy . . . . . M<sub>175</sub>, T<sub>100</sub>, T<sub>104</sub>, W<sub>163</sub>
- MRI . . . . . T<sub>25</sub>, M<sub>144</sub>, 16, T<sub>28</sub>, T<sub>41</sub>, T<sub>161</sub>
- mRNA . . . . . W<sub>252</sub>
- MRS . . . . . M<sub>22</sub>, M<sub>262</sub>, 12, W<sub>19</sub>
- mTOR . . . . . M<sub>230</sub>, W<sub>75</sub>
- mu-opioid receptors . . . . . M<sub>261</sub>, 58
- multi-episode schizophrenia . . . . . M<sub>166</sub>
- Multiplex families . . . . . T<sub>163</sub>
- multivariate . . . . . T<sub>189</sub>, W<sub>176</sub>
- muscarinic acetylcholine receptor . . . . . T<sub>65</sub>, W<sub>125</sub>, W<sub>173</sub>
- myoinositol . . . . . W<sub>19</sub>

**N**

- N-acetylcysteine . . . . . M<sub>241</sub>
- Na<sup>+</sup>/H<sup>+</sup> exchanger . . . . . 57
- NAcore . . . . . W<sub>257</sub>
- NADPH oxidase . . . . . M<sub>92</sub>
- Naltrexone . . . . . M<sub>254</sub>
- national representative sample . . . . . W<sub>230</sub>
- national study . . . . . W<sub>230</sub>
- Native American . . . . . W<sub>215</sub>
- Native Americans . . . . . M<sub>53</sub>
- natural history genomic studies . . . . . W<sub>169</sub>
- negative emotionality . . . . . W<sub>255</sub>
- Negative Symptoms . . . . . M<sub>155</sub>, M<sub>158</sub>, M<sub>204</sub>, W<sub>188</sub>
- neural activity . . . . . T<sub>188</sub>
- neural circuitry . . . . . 23, T<sub>35</sub>, W<sub>80</sub>
- neural circuits . . . . . M<sub>119</sub>, M<sub>209</sub>, 14, 55
- neural plasticity . . . . . M<sub>189</sub>, T<sub>54</sub>
- Neuregulin . . . . . W<sub>138</sub>
- Neuregulin-1 . . . . . W<sub>160</sub>
- neuregulin-3 . . . . . T<sub>223</sub>
- neurogenesis . . . . . M<sub>207</sub>
- neuroactive steroid . . . . . M<sub>74</sub>
- neuroanatomy . . . . . T<sub>36</sub>
- neurobiology, stress, depression, anxiety, adolescence . . . . . M<sub>14</sub>, M<sub>32</sub>, W<sub>96</sub>
- neurochemistry . . . . . T<sub>200</sub>
- neurocircuitry . . . . . M<sub>40</sub>, 43
- neurocognition . . . . . M<sub>189</sub>, T<sub>108</sub>, T<sub>154</sub>, T<sub>164</sub>, T<sub>175</sub>, W<sub>77</sub>, W<sub>189</sub>
- neurodegeneration . . . . . T<sub>141</sub>, W<sub>139</sub>
- neurodegenerative . . . . . T<sub>141</sub>
- Neurodegenerative Disease . . . . . M<sub>146</sub>
- Neurodevelopment . . . . . M<sub>146</sub>, M<sub>220</sub>, 34, 37, 42, W<sub>34</sub>, W<sub>130</sub>, 48

**Keyword Index**

- Neurodevelopmental Disorders . . . . . T32, W149, W196  
 neuroeconomics . . . . . W164  
 Neuroendocrine . . . . . M63  
 Neuroendocrine system . . . . . T246  
 neuroendocrinology . . . . . T66  
 Neurofeedback . . . . . 47  
 Neurogenesis . . . . . M138, T49, T109  
 neurogranin . . . . . T160  
 Neuroimaging . . . . . M150, T75, T96, T215, 34,  
     W36, W55, W219, W226, 6  
 neuroimmune . . . . . M117, W253  
 Neuroimmunology . . . . . W204  
 Neuroinflammation . . . . . M89, M110, M188, 12, T76, 40,  
     T205, W81, W107  
 Neurological disorder . . . . . M143  
 Neuromodulation . . . . . T191, W121  
 Neuronal Epigenome . . . . . W52  
 neurons . . . . . T126, W181  
 neuropeptide Y . . . . . M73  
 Neuropeptides . . . . . W59  
 neurophysiological aspects of the origin of  
     consciousness, . . . . . T134  
 Neuropil . . . . . W188  
 Neuroplasticity . . . . . 20, T211, W52, W210  
 Neuropsychiatric Adverse Events . . . . . M244  
 neuropsychiatric inventory . . . . . M145  
 neuropsychology . . . . . T186, T196, T260  
 Neuroreceptor imaging . . . . . T143, W45  
 neurosurgery . . . . . W18  
 Neurotechnology . . . . . W128  
 neuroticism . . . . . M236  
 neurotransmitter co-release . . . . . M125  
 new targets . . . . . W90  
 nicotine . . . . . M97, M136, M235, T129, T220,  
     T243, T255, T257, W211,  
     W235, W252  
 nicotine addiction . . . . . T237, W238  
 Nicotine dependence . . . . . M244, M249, T223, T248, W221  
 nicotinic acetylcholine receptors . . . . . M97, M136, M162,  
     T212, T248, W238  
 NIH . . . . . 8  
 nitric oxide . . . . . T214, T251  
 nitric oxide donor . . . . . M205  
 NMDA . . . . . W199  
 NMDA Antagonists . . . . . M18, M160, T49  
 NMDA channel blocker . . . . . M212  
 NMDA glycine-site receptor . . . . . M158, W245  
 NMDA Receptor . . . . . 1, M62, M186, M212, T153, W2,  
     W185, W196, 29  
 NMDA Receptors . . . . . T183, W167  
 non pharmacological interventions . . . . . M100, 23, W205  
 non-linear . . . . . M121  
 Non-Pharmacological Therapy . . . . . M1, 45  
 Nonhuman Primate Models . . . . . M75, T261  
 Nonhuman Primates . . . . . M256, T237, W10, 56  
 norepinephrine . . . . . T11  
 not just right experience . . . . . M8  
 Notch . . . . . M126  
 novel object recognition . . . . . M214, W203  
 novel therapeutics . . . . . T169, W70  
 NPSR1 . . . . . M16  
 Nucleus Accumbens . . . . . M211, M213, T94, T214,  
     T242, T253, W8, W13, W62, W84,  
     W228, W234, 54  
 Nucleus Accumbens Shell . . . . . T213, W236, W257  
 Nutrigenomics . . . . . T48

**O**

- Obesity . . . . . T50, T58, T137, T246, 28, W8, W45,  
     W46, W133, W134, W226  
 Obsessive Compulsive Disorder . . . . . M22, 22, T125, T142,  
     T143, W11, W18, W19, W29  
 Obsessive-Compulsive and Related Disorders . . . . . M21  
 occupancy . . . . . W152  
 OCD . . . . . 7, M8, M18, M22, T22, W9, 56  
 odor-related trauma . . . . . M17  
 older adults . . . . . M2  
 older patients . . . . . W172  
 Olfaction . . . . . M36  
 olfactory . . . . . M17, M192  
 Omega-3 Fatty Acid . . . . . M69, M82  
 open science . . . . . W169  
 opioid . . . . . M257, T228  
 Opioid dependence . . . . . T217, W232  
 Opioid system . . . . . 4, T224  
 opioids . . . . . M238, M258  
 OPRM1 A118G . . . . . T224  
 optogenetics . . . . . 7, M76, M119, M137, M218, T19,  
     T55, T158, T233, T259, W62, W117  
 Orbitofrontal cortex . . . . . T238, W9  
 orexin . . . . . W15  
 organic cation transporters . . . . . T61, 57  
 oscillation . . . . . M33  
 ovarian steroids . . . . . M116  
 oxidative stress . . . . . M22, M67, M194, T39  
 OXTR . . . . . W146  
 oxytocin . . . . . M122, M132, 24, T190, T226, T242, 27,  
     W146, W164, W261

**Keyword Index****P**

- P300 ..... W193  
 p38 MAPK ..... W50, W75  
 P50 ..... M25  
 PACAP ..... T20, T115, T120, W59  
 Pain ..... M142, M238  
 pair bond ..... W131  
 Palatable food ..... T49  
 paliperidone ..... T195  
 paliperidone palmitate ..... T187, W154  
 panic ..... T14, W15  
 panic attacks ..... M16  
 PANSS ..... T204, W150  
 Parkinson's disease ..... W138  
 Parkinsonism ..... 57  
 parvalbumin ..... M31, T160, T197, W183, 53  
 parvalbumin interneurons ..... M157, M169, T158, T199, W155, W234  
 pathological gambling ..... M223  
 pathophysiology ..... M178, M194, 30  
 Pavlovian ..... M218  
 Pavlovian conditioning ..... M242, W251  
 PDE2 ..... M92  
 PDE4 ..... M184, M228  
 pediatric ..... T22, W32  
 penetrance ..... W32  
 Perimenopause ..... M113  
 perinatal ..... W229  
 perinatal anxiety ..... T103  
 perinatal depression ..... T103  
 Peripheral Nerve Stimulation ..... W121  
 personality ..... W99, W122  
 PET ..... 2, M58, M70, M123, M144, M151, W156, M159, M226, T135, T150, T180, W174  
 PET Imaging ..... M146, T140, W42, W123  
 PET study ..... M227, 40  
 PFC ..... W173  
 Pharmacodynamics ..... W137  
 pharmacogenetic ..... W15  
 Pharmacogenetics ..... M59, M220, T127, T174, 60  
 Pharmacogenomics ..... M195, W86, W87, W168, 48  
 Pharmacokinetics ..... M34, T232  
 Pharmacology ..... T56, T132, T169, 50  
 Pharmacotherapy ..... M21, M239  
 phase of illness ..... T193  
 phencyclidine ..... W203  
 Phenotype Screening ..... 41

- Phenotypes ..... M201, W255  
 Phosphodiesterase-4 (PDE4) ..... T42  
 Physical dependence ..... M129  
 physical exercise ..... M189  
 PKMzeta ..... M225  
 Placebo Response ..... W86  
 placebo-controlled trial ..... M81  
 Polygenic Risk Score ..... M183, W1  
 polymorphism ..... T124  
 POMC ..... M126  
 population -based ..... T194  
 positive allosteric modulators ..... T206, W125  
 Positron Emission Tomography ..... M54, M134, M216, T107, T143, T221, T248, W10, W60, W182  
 postmortem ..... T198  
 Postmortem Brain Tissue ..... M147, M196, M197, T43, T179, W42, W153, W200  
 postmortem human brain ..... M207, W69  
 postpartum ..... M140  
 Postpartum depression ..... M74, T116, T66  
 posttraumatic stress ..... M7, T23  
 Posttraumatic stress disorder ..... M15, M26, M61, T12, T18, W88, 47  
 poverty ..... M40  
 prairie voles ..... W131  
 Precision Medicine for Depression ..... M108  
 Preclinical ..... M129  
 Preclinical Trial Methodology ..... T1  
 precuneus ..... T35  
 prediction ..... 19  
 Predictive Models ..... T166, W189  
 Prefrontal cortex ..... W149  
 prefrontal circuit ..... W65  
 Prefrontal cortex ..... M28, M96, M102, M162, M164, M165, M202, M221, T24, T28, T188, T207, T215, W2, W60, W217  
 prefrontal-amygdala-connectivity ..... M32  
 Pregabalin ..... W53  
 pregnancy ..... M25, M74, T79, T232  
 prelimbic ..... W214  
 premenstrual dysphoric disorder ..... M116, T78  
 prenatal ..... M44  
 prenatal smoking ..... W29  
 prenatal stress ..... M31, T40, 33  
 Prepulse Inhibition ..... W187  
 Prescription drug abuse ..... W230  
 prevalence ..... W24  
 Prevention ..... M112, T116, 45

**Keyword Index**

- Prevention of Alzheimer's disease . . . . . M43, T1  
 primate model . . . . . W22  
 probabilistic reasoning . . . . . T192  
 Probabilistic reinforcement . . . . . W161  
 Progesterone . . . . . M113, T66, W246  
 propanolol . . . . . T9  
 protein aggregation . . . . . T184  
 Proteomics . . . . . W200  
 proteostasis . . . . . T184  
 Pseudobulbar affect . . . . . T145  
 Psychiatric Comorbidity . . . . . M103, M148  
 psychiatric disorders . . . . . M194  
 psychiatric genetics . . . . . M181, M229  
 psychiatry . . . . . W136  
 psychoeducation . . . . . W40  
 Psychoneuroimmunology . . . . . M75, T100, W135  
 psychophysiology . . . . . T15, T78  
 psychosis . . . . . M174, M203, M212, T166, T186, T190, T204, W40, W162, W191  
 psychosis continuum . . . . . W159  
 psychosis risk . . . . . 37  
 psychosocial stress . . . . . W135  
 psychosomatic medicine . . . . . W135  
 Psychostimulant . . . . . T221, W261  
 Psychotherapy . . . . . M9, M10, T12  
 psychotic disorders . . . . . 30  
 PTSD . . . . . M6, M10, M17, M19, M23, M138, T8, T10, T15, 41, W17, W21, W23, W53, W74, W120, W147  
 pyramidal neuron . . . . . M185
- Q**
- QTG . . . . . M229  
 QTL . . . . . M219, M229  
 Quantitative Electroencephalography (qEEG) . . . . . T209
- R**
- R-fMRI . . . . . W63  
 Rabies tracing . . . . . M217  
 Radiotracer . . . . . M146  
 raloxifene . . . . . M152  
 Raman spectroscopy . . . . . T126  
 Randomised clinical trial . . . . . M47  
 randomized clinical trial . . . . . M100, W184  
 raphe . . . . . T55
- Rapid Antidepressant . . . . . W57  
 rare variation . . . . . W33, W201  
 Rat . . . . . M46, M102, M129, T68, T238  
 rat strains . . . . . M136  
 Rating scales . . . . . W129  
 Reappraisal Training . . . . . M149  
 reasons for change . . . . . W215  
 recollection . . . . . T193  
 Recovery . . . . . W227  
 Recurrence risk . . . . . W56  
 Redox modulation . . . . . T39, 29  
 Regeneration . . . . . W123  
 reinforcement . . . . . T31  
 Reinforcement learning . . . . . M155, T89, W161, W262  
 reinstatement . . . . . M243, T235, W231  
 rejection . . . . . W216  
 relapse . . . . . M235, M240, M252, W214, W248  
 Relapse Prevention . . . . . M21, T170, T195  
 relatives . . . . . M199  
 Religion . . . . . M127  
 repetitive behavior . . . . . 7  
 repetitive transcranial magnetic stimulation . . . . . T112, 47  
 Replication . . . . . 8  
 Reproducibility . . . . . 8  
 reproduction . . . . . T20  
 Research domain criteria (RDoC) . . . . . M5, M7, M109, W158  
 Resilience . . . . . M11, M87, M209, W52, W145  
 Resting state . . . . . T18, T216  
 resting state fMRI . . . . . T34, T69  
 Resting State Functional Connectivity . . . . . M5, M14, M135, M236, T26, T36, T99, T101, T125, T149, T234, T239, T240, T243, W44, W85, W90, W101, W192, W197, W202, W209, W222, W235, W244, 46
- Rett Syndrome . . . . . T37  
 reversal learning . . . . . T257  
 Reward . . . . . M122, M254, M260, T47, T50, T94, T171, T238, W108, W161, W250, W251  
 reward neural circuitry . . . . . M105, T46, W37, W90  
 reward pathway . . . . . M238  
 reward prediction error . . . . . W13, W262  
 reward processing . . . . . M223, 21, T246, 36, 44  
 reward system . . . . . M132, T33  
 Reward-based decision-making . . . . . T257, W79, W157  
 RhoA . . . . . T225  
 RiboTag . . . . . W228  
 riluzole . . . . . M86, M243  
 Risk . . . . . M87, M131, T194, T217  
 risk taking behaviors . . . . . M252

RNA binding protein ..... M229  
 RNA Sequencing ..... M116, T57, T127, W30, W42  
 RNA splicing ..... T178  
 RNA-seq ..... M96, T54, W10  
 ROC analysis ..... M145  
 rTMS ..... M30

**S**

S-glutathionylation ..... M133  
 safety ..... W172  
 Salience ..... W117  
 salience network ..... T18, W11, W222  
 Satiety ..... M72  
 Schizophrenia ..... 1, M27, M147, M152, M153, M154, M156, M157, M158, M159, M161, M164, M167, M170, M171, M172, M173, M174, M179, M180, M181, M183, M188, M189, M191, M192, M193, M195, M197, M198, M199, M201, M204, M205, M206, M208, M235, T131, T151, T152, T153, T154, T156, T157, T158, T159, T160, T161, T162, T163, T164, T168, T169, T170, T171, T172, T177, T179, T181, T183, T184, T188, T189, T193, T194, T195, T196, T197, T199, T200, T202, T203, T204, 32, 39, 42, W152, W153, W156, W159, W160, W161, W162, W163, W164, W165, W169, W171, W172, W174, W176, W179, W180, W182, W186, W194, W195, W196, W204, 29, 50, 53  
 schizophrenia genetics ..... M183, T192, W167, W175, W201  
 schizophrenia prodrome ..... M163, W190, W198  
 Schizophrenia, Dopamine, Antipsychotics ..... M151, M165, M168, M169, W166  
 schizophrenia, moderators ..... T175  
 Schizophrenia-like Behavior ..... M184, W170  
 schizotypy ..... W167  
 Scopolamine ..... T65, W58, W64  
 Scoring Accuracy ..... W150  
 screening ..... W199  
 seasonal affective disorder ..... W60  
 selective estrogen receptor modulator ..... M152  
 Self-Administration ..... M221, M231, M234, M240, T237, T242, T261, W225, W231, 54  
 self-injury ..... M38  
 Sensitive Period ..... 20, W35  
 sensitization ..... T221, T255, W250  
 sensorimotor ..... T45

sensory gating ..... M184  
 sensory processing ..... M8  
 septum ..... M79  
 sequencing ..... 25, W148  
 Serious Mental Illness ..... M200, W132  
 Serotonin ..... M73, M77, M79, T72, 33, W5, W81, W116, W127, W178, W242  
 Serotonin 1b receptor ..... M58, T53  
 serotonin 2A ..... T182, T252  
 Serotonin 5-HT2C Receptor ..... M134, W175  
 Serotonin 5-HT7 ..... W236  
 serotonin reuptake inhibitors ..... T107  
 Serotonin Transporter ..... M12, M60, T229, W60, W123  
 SERT ..... W166  
 sex difference ..... M69, M97, M109, 9, 34, W6, W241  
 Sex differences ..... M12, M80, M251, T3, T6, T33, T60, W98, W118, W134, W219, W246  
 Sexual Dimorphism ..... 9, T98  
 sexual dysfunction ..... T114  
 Sheehan Suicidality Tracking Scale ..... M127  
 short-acting Kappa opioid receptor antagonist ..... M104  
 sibling ..... T194, W77  
 sign-tracking ..... W126  
 Skin conductance response ..... W118  
 skull shape ..... W28  
 SLC6A4 ..... W14  
 sleep ..... M114, M139, T34, T44, T128, T209, W110, W208  
 sleep disturbance ..... M226, W16  
 sleep spindles ..... T158, T191  
 Slitrk5 ..... 22  
 slow waves ..... T44  
 smartphone ..... W206  
 Smoking ..... M259, T210, W156, W229  
 Smoking Cessation ..... T227, M244  
 Smoking urge ..... M242, T226  
 SNP ..... W167  
 sociability ..... M36  
 Social ..... T148, W247  
 Social Anxiety ..... T7, W12  
 Social buffering ..... W80  
 social cognition ..... M203, M254, 24, T154, 36  
 Social Competence ..... T176  
 Social defeat stress ..... M33, M57, M61, M230, T81, T118, T233, W59, W80, W108  
 Social Functioning ..... T111  
 social interaction ..... T115, W216  
 social neuroscience ..... M40, M122, T146  
 social recognition memory ..... T190, T193

Social Rhythms . . . . .	M115	T
Social stimuli . . . . .	T228	
social stress . . . . .	38, W38	
social subordination . . . . .	W244	
Source Localization . . . . .	M164	
SPECT . . . . .	W152	
Spice/K2 cannabinoids . . . . .	T250	
spines . . . . .	T225	
SSRI . . . . .	M186, T69, T80, T97, W93	
startle latency . . . . .	M171	
statistical methods . . . . .	T231, W111	
stereotypy . . . . .	M38	
stimulant . . . . .	T9	
Stimulant Abuse . . . . .	W249	
Stress . . . . .	M63, M64, M76, M94, M102, M249, T110, T120, W6, W22, W52, W94, W98, W214, 49	
Stress circuits . . . . .	T67	
stress response circuitry . . . . .	M109, 10	
striatum . . . . .	M27, M262, T33, T69, T135, W63	
Stroke . . . . .	T145	
structural covariance . . . . .	T26	
Structural MRI . . . . .	M24, M40, M181, M190, T41, T173, T189, 37	
Subcallosal Cingulate . . . . .	W76, 59	
Subclinical psychosis . . . . .	T41, T176, W190	
subgenual . . . . .	T86, T99	
Subjective Cognitive Impairment . . . . .	T1	
subjective effects . . . . .	T129, T220, W224	
Substance abuse . . . . .	M232, 17, T183	
Substance use . . . . .	W154	
substance use disorder . . . . .	5	
Substance-related disorders . . . . .	T50, W233	
subthalamic nucleus . . . . .	W209	
Subtypes . . . . .	46	
Suicide . . . . .	M83, M127, T5, T52, T56, W65, W69, W84	
Suicide Assessment . . . . .	T27, W57	
suicide behavior severity . . . . .	M93	
sunshine act . . . . .	35	
sustained attention . . . . .	T24	
SV2A protein . . . . .	W3	
synapses . . . . .	T43	
synaptic connctions . . . . .	W155	
Synaptic Plasticity . . . . .	M137, M245, 18, T223, T251, 28, W4, W143, W234, W250, 49	
synaptic spine . . . . .	M205	
Synthesis . . . . .	T72	
systemic inflammation . . . . .	M110, W109, W135	
systems biology . . . . .	3, 34	
targeted cognitive training . . . . .	M180	
task-based functional connectivity . . . . .	M17	
tau . . . . .	T141	
Technology . . . . .	M115	
telemetry . . . . .	W208	
Telomere . . . . .	W233	
temperament . . . . .	W99	
Test Retest . . . . .	M72	
testosterone . . . . .	T11	
Thalamus . . . . .	T74, W188	
THC . . . . .	W7, W259	
threat . . . . .	T17	
Threat Conditioning . . . . .	W53	
Threat of Shock . . . . .	T9, W23	
thyroid . . . . .	T103	
tianeptine . . . . .	58	
timing . . . . .	W178	
TMS . . . . .	M164, W102	
Tobacco Smoking . . . . .	M247	
Tolerability . . . . .	M193	
Tolerance . . . . .	W221	
Tourette syndrome . . . . .	7, T143, W29	
toxoplasmosis . . . . .	M44	
trace amine-associated receptor 1 . . . . .	W231	
Tractography . . . . .	M60, M106, W100, 59	
Training . . . . .	M124, 26, T133	
Trajectories . . . . .	W36	
transcranial current stimulation . . . . .	T191	
Transcranial Magnetic Stimulation . . . . .	T27, T107, T168, T211, W112, W260	
transcription . . . . .	W183	
transcription factor . . . . .	T165, W243	
transcription factors . . . . .	10, W143	
Transcriptomics . . . . .	3, T54, W143	
transgenerational . . . . .	T40	
transgenic mice . . . . .	M76, M185	
TRANSGLUTAMINASE 2 . . . . .	M84	
translational imaging . . . . .	W260	
Translational Neuroscience . . . . .	M135, T133	
Transporters . . . . .	M130	
Trauma exposure . . . . .	6, M5, W53, W109, W118, W120	
trauma history . . . . .	T103	
Traumatic Brain Injury . . . . .	T145	
Traumatic stress . . . . .	M246	
Treatment . . . . .	M224, M241, T217, 46, W78, W246	
Treatment Outcome Prediction . . . . .	M78, M237, T1, T254	

**Keyword Index**

- treatment refractory.....T82  
Treatment resistance ..... T203, W162  
Treatment Resistant Depression ..... M65, M103, T80, T85, T93, T97, T106, W100, W112, W114  
treatment response .....M195, 27, W168, W175  
TrkB ..... M233, T102  
trust .....W164  
Tryptophan ..... W141, W195  
Tryptophan depletion.....T72  
TSPO ..... T140  
TSPO and [11C]PBR-28 PET ..... M89, M227, 12, W182  
twins.....T200  
type 2 diabetes mellitus ..... M141, T83, W109  
Type-2 Diabetes.....W46
- U**
- UCSD Performance-Based Skills Assessment (UPSA) ..M71  
ultra high-risk youth .....M163  
Unconditioned responses .....W120  
upregulation ..... W227  
uptake 2 .....T61  
User-centered design .....M101, T133
- V**
- Vagus Nerve Stimulation .....W121  
Varenicline .....M235, M253, T257  
ventral hippocampus ..... M19, M96, T16, T81  
Ventral Striatum .....M182  
Ventral Tegmental Area ..... M209  
Ventral tegmental area (VTA) .. M125, M217, M218, M230, T55, T247, W217, W262  
ventrolateral prefrontal cortex .....T104, W38  
Verbal Memory ..... W82  
vesicular glutamate transporter (VGLUT) .....M125  
violence.....T149  
Virtual Reality.....W157
- vmPFC .....W238  
voltammetry ..... M232, M256, W58, W127  
Vortioxetine ..... M71, W83  
voxel-based morphometry (VBM)..... T189, W18, W176  
VTA ..... W80  
Vulnerability .....M231, 9, T21
- W**
- wakefulness..... W208  
wheel running ..... W73  
White Matter ..... M106, M191, W194, W195  
Whole exome sequencing..... M53, M116, W33, W201  
williams syndrome..... W28  
Withdrawal ..... M249, M252, M257, T256, W31  
women ..... W219, W224  
Women's Mental Health..... T79, W109  
work readiness ..... T187  
working memory ..... M42, M135, M198, M221, T165, T180, W2, W180, W187, W207  
Working Memory Capacity ..... T9  
working memory fMRI..... W151, W171
- X**
- xCT ..... W220
- Y**
- Yoga ..... M1, T162
- Z**
- zebrafish ..... T132  
ziprasidone ..... M103  
ΔFosB ..... T81